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Abstract 
Background: Subcutaneous implantable cardioverter defibrillators (S-ICD) are an alternative 
to conventional transvenous implantable cardioverter defibrillators (TV-ICD) in patients not 
requiring pacing.  We sought to define the efficacy and safety of S-ICD through literature 
review. 
Methods: We searched MEDLINE and EMBASE for studies evaluating efficacy and safety 
outcomes among patients undergoing S-ICD implantation.  We performed narrative synthesis 
and pooled efficacy and safety outcomes across studies. 
Results: 16 studies were included with 5,380 participants (mean age range 33–56 years).  
Short-term follow-up data were available for 1670 subjects.  The commonest complication 
was pocket infection, affecting 2.7% (range 0–19%).  Other complications included delayed 
wound healing (0.6%), wound discomfort (0.8%), haematoma (0.4%) and lead migration 
(0.3%).  A total of 3.8% (range 0–12%) of S-ICDs were explanted.  The commonest reason 
for explant was pocket infection.  Mortality rates in hospital (0.4%) and during follow-up 
(3.4% from 12 studies reporting, 2.1% per person-years) were low. The number of patients 
experiencing ventricular arrhythmia varied across studies from 0 to 12%. Overall shock 
efficacy for treatment of ventricular arrhythmias exceeded 96%.  Inappropriate shocks 
affected 4.3% (range 0–15%) of patients and was most commonly caused by T-wave 
oversensing. 
Conclusions: Although long-term randomised data are lacking, observational data suggest 
shock efficacy, peri-procedural and short-term complication rates of the S-ICD are similar to 
TV-ICD, making the S-ICD a suitable alternative in patients without an indication for pacing. 
 
 
 
Introduction 
 The implantable cardioverter defibrillator (ICD) is recommended to prevent sudden 
cardiac death from ventricular tachyarrhythmia in patients with primary and secondary 
prevention indications.  The transvenous ICD (TV-ICD) is an established therapy with 
excellent outcome data.  However, implant-related complications associated with transvenous 
lead placement, including pneumothorax, cardiac perforation and tamponade, occur in 3%, 
[1] while long-term complications such as infection, endocarditis and lead failure occur in up 
to 20% of TV-ICD leads at 10 years.[2]  Extraction of transvenous leads carries significant 
morbidity and mortality.[3]  The subcutaneous defibrillator (S-ICD) system is entirely 
extravascular, offering the potential to address these shortcomings.[4] 
 The S-ICD was originally developed by Cameron Health and received FDA approval 
in 2012.  The second-generation device (EMBLEM) is manufactured by Boston Scientific.  
The system is fully extravascular with a lead that is not subjected to the same stresses as a 
transvenous lead and does not have a lumen, thus reducing the long-term risk of lead failure.  
In the event of lead failure, removal of the S-ICD lead is not associated with the hazards of 
vascular or intracardiac complications as seen with TV-ICD lead extraction.  The main 
limitation of the S-ICD is that it does not provide anti-tachycardia pacing (ATP), and other 
than a short period of post-shock pacing, cannot provide sustained pacing for 
bradyarrhythmia.  A few reviews of the S-ICD system have evaluated many of the studies[5-
7] but these reviews do not pool clinical outcomes. 
 
 Initial short-term outcome data from a number of observational studies are favourable 
with low complication rates when compared to the TV-ICD.[8,9]  However, many of these 
reports stem from single centres and include small patient numbers.  We reviewed current 
evidence supporting the use of S-ICD devices from primary evaluations of efficacy and 
safety outcomes. 
 
Methods 
Search strategy and study eligibility 
 A search of MEDLINE and EMBASE was performed on 21 April 2016 using the 
search terms: "(subcutaneous ICD) OR (subcutaneous implantable cardioverter 
defibrillator)."  Two independent reviewers (CSK and CDC) reviewed the titles and abstract 
for potential inclusion.  Articles, including conference abstracts, were considered if they were 
primary studies of S-ICD reporting quantitative safety and efficacy outcomes.  Case reports, 
studies of fewer than ten participants, letters and editorials were excluded but relevant 
reviews were retrieved to identify additional studies.  The full manuscripts of screened results 
were retrieved and final inclusion was determined by two independent reviewers (CSK and 
CDC) with adjudication by a third (FA). 
 
Data extraction and analysis 
 Independent data extraction was performed by two reviewers (CWW and CDC), 
including information on study design, patient demographics, follow-up and results.  The 
extracted data was independently checked by two other reviewers (FA and CC).  Data 
synthesis was performed by CSK and CDC by pooled analysis.  Using Microsoft Excel, we 
conducted a pooled analysis of all reported efficacy and safety events.  For a common 
outcome across different studies, the number of patients with events was summated across 
studies and divided by the total number of participants to yield the pooled rate, which is 
expressed as a percentage.  Events during follow up were expressed as both a pooled rate and 
an event rate per person-years of follow up.  Person-years were calculated by multiplying the 
number of subjects by the mean period of follow up in years. 
 
Results 
Study selection 
A total of 16 studies were included and the process of study selection is shown in 
Figure 1. [10-26] 
 
Study participant characteristics 
The 16 studies took place between 2009 and 2015.  Study size ranged from 18 to 3717 
subjects, with a total of 5380 patients undergoing S-ICD implantation (Table 1).  The largest 
analysis of 3717 patients was from the National Cardiovascular Data Registry, reporting in-
hospital outcomes for S-ICD implantation in the US.[14]  The second largest study of 889 
participants was an international pooled analysis of subjects recruited into the IDE (S-ICD 
system Investigational Device Exemption Clinical Study) and EFFORTLESS trials, reporting 
follow-up data to 2 years.[11] 
  
 Mean age of patients ranged from 33 to 64 years with 62–92% of patients being male.  
Most patients (68%) had a primary prevention indication (Table 2).  Ischaemic heart disease 
was present in 42%.  A further 44% had non-ischaemic cardiomyopathy.  The remaining 14% 
had congenital heart disease, a channelopathy, idiopathic ventricular fibrillation or other 
unstated diagnosis.  Mean follow-up, excluding studies reporting only in-hospital outcomes, 
ranged from 61 to 2117 days (4 to 1585 patient years). 
Adverse outcomes 
 Reported complications and their frequency are shown in Table 3.  The commonest 
complication was pocket infection (2.7%, range 0–19%, 14 studies, 44 events/1654 total 
participants, 1.7% per person-years of follow up).  Other complications included delayed 
wound healing (0.6%, 7 studies, 7 events/1145, 0.4% per person-years of follow up), wound 
discomfort (0.8%, 9 studies, 10 events/1327, 0.5% per person-years of follow up), 
haematoma (0.4%, 10 studies, 22 events/5044, 0.5% per person-years of follow up) and lead 
migration (0.3%, 10 studies, 14 events/5059, 0.4% per person-years of follow up).  Device 
malfunction included premature battery depletion (1.2%, 10 studies, 16 events/1384, 0.7% 
per person-years of follow up) and failure to communicate with the device (0.3%).  The 
highest rate of premature battery depletion was 9% in an early cohort study.[22]  A battery 
manufacturing issue was identified that led to a field safety notification in June 2011.  
Subsequent rates of premature battery depletion were lower (0.6% in the pooled analysis of 
the IDE study and EFFORTLESS registry).[11]  Mortality rates in hospital and during follow 
up were 0.4% (10 studies, 15 events/4235) and 3.4%(12 studies, 52 events/1547) 
respectively.  Follow up arrhythmic death was confirmed in two study participants (0.1%).  
Other causes of death were not stated. 
 A total of 3.8% (range 0–12%) of S-ICDs were explanted from 11 studies (57 
events/1514; 2.2% per person-years of follow up; Supplementary Table 1), most commonly 
for pocket infection (1.8%, 29 events/1585, 1.1% per person-years of follow up).  Other 
explant indications included need for pacing, inappropriate shocks (IAS) and unsuccessful 
defibrillation threshold (DFT) testing.  Where described, 16 patients undergoing S-ICD 
explant subsequently received a TV-ICD (16 events/36, 44%).  Generator repositioning or 
explant for erosion was required in 1.5%; this was highest in a published cohort from UK 
centres (8%).[17] In the series with the longest follow-up period (mean 2117 days), most 
device removal (25/31) was for elective battery replacement.[22]  Median device longevity 
was 5 (4.4–5.6) years. 
Defibrillator threshold testing 
 A total of 77% of patients undergoing S-ICD implantation underwent DFT testing 
(range 75–100% from studies reporting on DFT testing; Supplementary Table 2).  This was 
successful on the first attempt in 89% of cases (range 70–100%).  Reprogramming to reverse 
shock polarity or increasing to maximum output improved DFT success to 96%.  A further 
2% of patients had successful DFT following repositioning of the generator.  The device was 
explanted in 0.4% due to high DFT testing.  In the largest cohort, DFT success rates were 
92.7% at ≤65J and 99.7% at ≤80J.[26]  Submuscular placement of the S-ICD generator did 
not affect the DFT.[21]  In a small cohort of patients with hypertrophic cardiomyopathy 
(HCM), DFT was effective in all those tested at 65J.[24]  A 50J shock was effective in 80% 
and a 35J shock effective in 83% of those tested.  The DFT was higher with increasing 
BMI.[24] 
 
Shock efficacy 
 The number of patients experiencing VF or sustained VT varied from 0 to 12%.  
Many studies did not detail the number of episodes of sustained ventricular arrhythmia.  
Eight studies offered information on shock efficacy.  First shock efficacy varied from 58% in 
one study (95% CI 36–77%) [10] to 90% in the largest cohort study.[11]  Overall shock 
efficacy of the S-ICD system for treatment of ventricular arrhythmias is reported at 
≥96%.[10,11,17]  Aydin et al calculated an overall shock efficacy of 96.4% (95%  confidence 
interval 12.8-100%).[10]  In the pooled analysis of the IDE study and EFFORTLESS 
registry, 90.1% of VT/VF was terminated with the first shock and 98.2% terminated within 
the 5 shocks available.[11]  In the UK multicentre study all 24 appropriate shocks delivered 
for VT/VF successfully terminated the arrhythmia.[17] 
Inappropriate shocks 
 Inappropriate shocks (IAS) affected 4.3% (range 0–15%, 2.9% per person-years of 
follow up) of patients receiving an S-ICD (Supplementary Table 3).  The commonest cause 
was T-wave oversensing (TWOS).  Inappropriate therapy due to supraventricular tachycardia 
(SVT) and artefact from noise or myopotentials was rare.  A software upgrade introduced in 
October 2009 reduced rates of IAS due to TWOS.  However, 15% of patients in one series 
experienced IAS with devices that had the upgrade,[17] and 22% of HCM patients had at 
least one IAS in another recent study.[15]  Inappropriate therapy also decreased following 
introduction of dual zone programming and with reprogramming of the sensing vector.[15] 
Studies with matched transvenous implantable cardioverter defibrillator controls 
 Three non-randomised studies matched a total of 2060 patients undergoing S-ICD 
implantation with TV-ICD controls.[18,20,26] Most (1920) of these patients were from a US 
propensity-matched cohort comparing in-hospital outcomes.[14]  There were more 
pericardial effusions (6 vs. 0), cardiac perforations (3 vs. 0) and pneumothoraces (8 vs. 0) in 
the TV-ICD group but fewer haematomas (3 vs. 9).  Rates of DFT success (90%, 60/97 vs. 
91% 59/65) were similar.  Implantation time was comparable at 71 minutes for the S-ICD and 
65 minutes for a single chamber TV-ICD.[18]  Length of hospital stay was also comparable 
(1.1 days for the S-ICD vs. 1.0 days for a single chamber ICD and 1.2 days for a dual 
chamber ICD).[14]  There were 18 lead revisions in the TV-ICD group compared to two in 
the S-ICD group.  Infection rates were similar (five in the TV-ICD group compared to two in 
the S-ICD group).  In the two studies with short-term follow-up, rates of appropriate (9/140 
for the TV-ICD vs. 3/140 for the S-ICD) and inappropriate therapy (4/140 for the TV-ICD vs. 
5/140 for the S-ICD) were similar. 
Subgroups 
 Two small, single centre studies examined S-ICD use in 34 HCM patients.[15,24]  
During follow up, 6 patients (18%) had TWOS, with 5 (15%) receiving IAS.  One device 
(3%) was explanted due to IAS.  Treatment of ventricular arrhythmias was successful in the 
one patient with sustained VT.[11]  Two studies compared patients requiring dialysis (45 
patients) with non-dialysis controls (120 patients).[13,19]  Rates of peri-procedural 
complications and DFT success were comparable.  Dialysis patients had a longer length of 
hospital stay.[19]  Although device-related infections were more frequent in the non-dialysis 
group (10/120 vs. 0/45), this difference did not reach statistical significance in either study.  
Rates of IAS were similar at follow-up (annual event rate 6.0% in the dialysis group vs. 6.8% 
in the non-dialysis group, P=0.51 and 11% vs. 8%, P=0.6), although there were more 
appropriate shocks in the dialysis group (annual event rate of 17.9% vs. 1.4% P=0.02 and 
22% vs. 6%, P=0.06.  Shock efficacy for ventricular arrhythmias was high and comparable in 
dialysis and non-dialysis patients.[19] 
 
Discussion 
 This review of 16 studies with 5380 S-ICD implants, demonstrates the safety and 
efficacy of this therapy.  The rate of implant-related complications was low. While shock 
efficacy is reported to be high, this finding is based on relatively low event rates and limited 
follow-up time.  The S-ICD is a promising alternative to the TV-ICD in patients without need 
for pacing when vascular access is limited or when complications associated with 
transvenous lead placement would pose excessive risk.  The S-ICD may also be a suitable 
replacement system for patients with an explanted TV-ICD. The S-ICD was shown to be 
effective at treating ventricular arrhythmias.  Although first shock efficacy was 58% in one 
early series of 40 patients,[10] a larger prospective registry of 889 patients demonstrated 90% 
efficacy.[11]  Overall shock efficacy is over 96%. This is comparable to the TV-ICD, which 
has first shock efficacy of approximately 90% and overall efficacy of over 98%.[27-30]  
Equivalent shock efficacy was not a documented outcome in the non-randomised studies 
comparing the S-ICD with the TV-ICD as the event rate was low,[14,20] although the 
sensitivity of arrhythmia algorithms in VF detection appears equivalent between the two 
systems at time of implant.[8]  Across all 16 studies, two S-ICDs were explanted for failure 
to convert a ventricular arrhythmia. 
 The rate of successful DFT was approximately 98%.  Success was lower with 
increased BMI, acute myocardial inflammation,[10] in HCM and in younger patients.[31]  
Success rates for DFT testing in the TV-ICD is similar at 95–98%.[32]  Interestingly, only 
77% of patients undergoing S-ICD implantation underwent DFT testing, despite the 
manufacturer’s recommendation.  This low rate of testing was accounted for mainly by the 
large US cohort study, in which only 2791 of 3717 patients underwent a DFT.[24]  The 
reason for this is unclear. 
 This review found implantation complication rates for the S-ICD comparable to those 
for the TV-ICD.  The National Cardiovascular Database ICD Registry reports a 3.1% risks of 
major in-hospital adverse events for the TV-ICD.[1]  The S-ICD carries no risk of 
haemothorax or pneumothorax as placement is entirely extrathoracic.  The commonest 
complication was pocket infection affecting 2.7% of implants, with 1.8% requiring 
subsequent device explant.  This was higher than the 0.7% infection rate for TV-ICDs.[33]  
The highest rates of pocket infection were reported in the UK series (12%),[17] but this was 
an early series reporting initial experience.  Procedure time, a factor that influences infection 
risk, was similar in a direct comparison of S-ICD with TV-ICD implantation,[18].  A two-
incision technique may lower wound complication rates and has not been associated with 
increased lead displacement or migration over 12 months of follow up in over 100 
patients.[16]  Submuscular device placement may reduce risk of erosion, although this has 
only been demonstrated in a small randomised single-centre study.[25]  In comparison with 
S-ICDs, there are limited data on the long-term performance of submuscular TV-ICDs.  
Submuscular placement was a contributory factor in the UK Medicines and Healthcare 
products Regulatory Agency advisory concerning header problems with the Boston Scientific 
Teligen ICD and there have been concerns that increased stress may increase the risk of 
premature lead failure.[34]  Submuscular placement is associated with increased morbidity 
during lead extraction[35] and longer procedure times compared to subcutaneous 
implantation.[36] 
 No lead failures were reported in the above studies and lead migration was 
uncommon (0.3%).  Premature battery depletion occurred in 1.2% of cases.  This improved 
following correction of a battery manufacturing issue.  Median battery longevity for the first 
generation S-ICD from the series with the longest follow-up period was 5 years.[22] 
However, Boston Scientific claim 40% increased longevity for the revised EMBLEM S-ICD, 
with an estimated lifespan of 7.3 years.  It is important to note that mean follow-up exceeded 
1 year in only 7 of the 16 studies, and only one study had mean follow-up exceeding 5 years.  
It is therefore beyond the scope of the current analysis to provide an accurate picture of the 
real-world rate of device malfunction, including premature battery depletion. 
  
 Rates of death and arrhythmic death were low during follow-up (3.4%, 2.1% per 
person-years, and 0.1% respectively).  One arrhythmic death occurred due to persistent VT 
falling below the programmed detection rate (180 bpm) for the device.[17]  Another death 
occurred in a patient deemed unsuitable for a TV-ICD due to obliteration of both the left and 
right ventricular apices with Loeffler’s syndrome, who experienced bradycardia prior to 
VF.[11] 
 The rate of device explant for patients developing a pacing indication was 0.6%.  In 
an early series 5% of S-ICDs were explanted due to the need for pacing or cardiac 
resynchronisation therapy (CRT).  However, 67% of this cohort had ischaemic heart disease, 
and the mean LVEF was 34%.[22] In studies of TV-ICDs, only 3–4% of patients develop 
bradycardia requiring pacing during subsequent follow-up device interrogation.[37]  This 
contrasts with heart failure patients, where frequency of upgrade to CRT varies from 4–
28%.[38,39] Patient selection prior to S-ICD implantation is critical, with particular 
consideration needed for patients with left ventricular systolic dysfunction, those with 
monomorphic VT amenable to ATP, and those likely to develop a pacing indication. 
 Inappropriate shocks affected 4.3% of patients, comparing favourably to the 2–10% 
for TV-ICDs.[40-43]  In MADIT-II 11.5% of patients with a TV-ICD experienced at least 
one IAS.[44]  Conservative programming reduced the annual IAS rate to 2.4–4%.[45,46]  
The highest IAS rate amongst S-ICD studies was in the UK registry (15%).[17]  Only a third 
of patients had dual zone programming at implant.  Dual zone programming utilises a VF 
zone, with detection determined solely by ventricular rate, and a second VT detection zone at 
a lower rate, which uses ECG morphology and stability criteria to discriminate between SVT 
and VT.  This significantly reduces rates of IAS.[47]  In the IDE study, dual zone 
programming reduced the 2-year IAS rate from 26.4% to 10.3%.[48]  Consequently, Burke et 
al reported a 34% decrease in 6-month incidence of IAS from the first quartile of patients 
enrolled into their combined registry compared to the last.[6]  Inappropriate therapy was also 
caused by TWOS in patients with HCM and congenital heart disease with abnormal baseline 
ECGs.  Rates of IAS were high in the HCM population due to large T waves and relatively 
small R waves, particularly during exercise.[21]  HCM is an independent predictor for lack of 
suitability for an S-ICD.[49]  Recommendations such as exercise-based examination of 
sensing vectors[47] and fulfilment of at least two ECG vectors instead of one highlight the 
importance of careful patient selection to reduce the risk of IAS.[13,18]  Altering the sensing 
vector post-implant can also reduce IAS. 
 Data from observational registries of S-ICDs compared to historical TV-ICD 
control populations are promising, although no randomised studies compare the S-ICD with 
the TV-ICD.[10,14,16]  The currently-recruiting PRAETORIAN trial aims to compare the S-
ICD and TV-ICD in 850 patients with a class I or class IIa ICD indication without need for 
pacing.  The results of this trial are eagerly awaited.[50] 
 
 There are limitations to our systematic analysis.  Aside from two reports, most other 
studies had fewer than 100 participants.  Most studies reported early experience of S-ICD 
implantation and therefore events rates may not reflect those of experienced centres.  This 
technology is still in its infancy and long-term data are still awaited.  There was also 
significant heterogeneity in reporting between studies.  A minority reported efficacy of DFT 
testing and reporting of complications was not standardised.  Duration of follow-up varied 
widely (61 to 2117 days), which may impact the complication rates reported. 
In conclusion, although randomised controlled trials with long-term safety data are 
lacking, observational studies demonstrate equivalent shock efficacy and similar 
complication rates for the S-ICD compared to the TV-ICD in patients without a pacing 
indication.  
Contributorship 
FA conceived and planned the study. CSK performed the search for relevant studies.  Data 
was screened by CSK and CDC and extracted by CDC, CWW, CC and FA.  Data analysis 
was performed by CSK and CDC.  CDC wrote the first draft of the paper. All authors 
contributed to the interpretation of the findings and critically revised it for intellectual 
content. 
Acknowledgements  
None. 
Funding: None. 
 
Competing Interests: None. 
 
List of Tables and Figures 
Table 1: Study design 
Table 2: Participant characteristics 
Table 3: Adverse outcomes 
Supplementary Table 1: Numbers of device explants 
Supplementary Table 2: Defibrillation testing 
Supplementary Table 3: Inappropriate shocks 
 
Figure 1: Flow diagram of study selection 
Table 1: Study design 
Study ID Study design, country, year No. of S-ICD 
implants 
Participant inclusion criteria Use of control Mean follow-up 
(days) 
Aydin 2012 Cohort. Germany. 2010–2011 40  Fulfil criteria for AHA/AHA prevention of primary/ 
secondary sudden cardiac death.  No bradycardia and 
no indications for ATP 
No 229 
Burke 2015 Cohort. Worldwide. 2009–2013 882 Primary and secondary prevention No 651 ± 345 
Eckardt 2011 Cohort. Germany. 2010 35 Primary and secondary prevention No 61 
El-Chami 2015 Retrospective cohort study (non-dialysis 
vs. dialysis).  USA.  2010–2015 
52 (non-dialysis) 
27 (dialysis) 
Participants with end-stage renal disease requiring S-
ICD for cardiomyopathy, stratified according to 
dialysis status. Primary and secondary prevention 
No 514 (non-dialysis) 
227 (dialysis) 
Friedman 2016 Cohort.  USA.  2012–2015. NCDR ICD 
registry 
3717 
 
All S-ICD implants Single and dual chamber transvenous ICD 
controls 
Not stated 
Fromeyer 2016 Cohort.  Germany.  2010–2015 18 S-ICD recipients with HCM No 951 
Hai 2015 Cohort.  Hong Kong and Singapore.  
2014–2015 
21 S-ICD implants No 107 ± 81 
Jarman 2013 Cohort.  UK.  Up to 2011 111 S-ICD implants No 381 
Kobe 2013 Cohort. Germany. 2010 69 All S-ICD implants and 69 age and sex matched 
controls with transvenous ICD 
Age-sex matched transvenous ICD 
controls 
217 ± 138 
Koman 2016 Cohort.  Germany.  2012–2015 68 (non-dialysis) 
18 (dialysis) 
Consecutive S-ICD implants in haemodialysis and non-
haemodialysis patients 
No 242 ± 238 (non-
dialysis) 
205 ± 208 (dialysis) 
Mithani 2016 Cohort.  USA.  2012–2015 71 S-ICD and 71 
matched TV-ICD 
Matched TV and S-ICD cases Age-sex matched transvenous ICD 
controls 
180 
Smith 2013 Cohort.  New Zealand.  2008–2012 73 S-ICD implants with Class I indications for primary 
and secondary prevention 
No 840 
Theuns 2015 Cohort.  Europe and New Zealand.  
2008–2009 
55 Class I, IIa/ IIb indication for ICD therapy No 2117 
Torres 2014 Cohort.  USA.  2010–2013 73 S-ICD implants in patients with congenital heart 
disease 
No At least 720 
Weinstock 2016 Cohort.  USA.  2012–2015 16 S-ICD implants in patients with HCM No 525 (median) 
Willner 2015 Cohort.  USA.  Year not stated 22 (submuscular) 
12 (subcutaneous) 
Submuscular and subcutaneous S-ICD implants No 110 
 
 
Table 2: Participant characteristics 
Study ID Mean age (years) % Male Primary prevention 
(%) 
Ischaemic 
cardiomyopathy (%) 
Other 
cardiomyopathy (%) 
Mean ejection 
fraction (%) 
Mean body mass 
index (kg/m2) 
Previous transvenous 
system (%) 
Aydin 2012 42 70 17 (42.5) 9 (23) 15 (38) 47 27 10 (25) 
Burke 2015 50 73 610 (69) 330 (37) 277 (31) 39 28 142 (16) 
Eckardt 2011 47 82 18 (51) Not stated Not stated Not stated Not stated 9 (26) 
El-Chami 2015 50 (non-dialysis) 
61 (dialysis) 
69 (non-dialysis) 
59 (dialysis) 
45 (87; non-dialysis) 
19 (70; dialysis) 
25 (48; non-dialysis) 
12 (44; dialysis) 
27 (52; non-dialysis) 
15 (56; dialysis) 
28 (non-dialysis) 
25 (dialysis) 
Not stated 6 (12; non-dialysis) 
4 (15; dialysis) 
Friedman 2016 54 69 Not stated 1687 (45) 1740 (47) 32 29 591 (16) 
Frommeyer 2016 35 83 14 (78) 0 (0) 18 (100) 63 Not stated Not stated 
Hai 2015 50 83 13 (62) 6 (29) 6 (29) 42 23 3 (14) 
Jarman 2013 33 (median) Not stated 55 (50) 15 (14) 35 (32) Not stated Not stated Not stated 
Kobe 2013 46 73 41 (59) 11 (16) 35 (51) 46 Not stated 16 (23) 
Koman 2016 62 (non-dialysis) 
64 (dialysis) 
62 (non-dialysis) 
67 (dialysis) 
41 (60; non-dialysis) 
5 (28; dialysis) 
28 (41; non-dialysis) 
9 (50; dialysis) 
31 (46; non-dialysis) 
7 (39; dialysis) 
29 (non-dialysis) 
30 (dialysis) 
31 (non-dialysis) 
28 (dialysis) 
13 (19; non-dialysis) 
4 (22; dialysis) 
Mithani 2016 Not stated Not stated Not stated Not stated Not stated Not stated Not stated 7 (10) 
Smith 2013 49 73 54 (74) 30 (41) 32 (44) 44 Not stated 5 (7) 
Theuns 2015 56 80 43 (78) 37 (67) 10 (18) 34 28 Not stated 
Torres 2014 40  Not stated 71 (97) 0 (0) Not stated 45 26 Not stated 
Weinstock 2016 40 Not stated 13 (56) 0 (0) 16 (100) 57 Not stated 4 (25) 
Willner 2015 54 (submuscular) 
56 (subcutaneous) 
86 (submuscular) 
92 (subcutaneous) 
Not stated Not stated Not stated 41 (submuscular) 
33 (subcutaneous) 
Not stated Not stated 
 
 
Table 3: Adverse outcomes 
Study ID Total patients Lead 
migration 
Pocket 
infection 
Haematoma Delayed 
wound 
healing 
Discomfort Premature 
battery 
depletion 
Failure of 
device 
communication 
Death in 
hospital 
Total deaths 
during 
follow-up 
Death rate per 
person-years (%) 
Aydin 2012 40 0 0 0 0 0 0 0 0 0 0 
Burke 2015 882 7 episodes 
(5 patients) 
17 episodes (14 
patients) 
4 3 8 5 3 Not reported 26 1.6 
Eckardt 2011 35 0 0 1 0 0 0 0 0 1 17.1 
El-Chami 
2015 
52 (non-dialysis) 
27 (dialysis) 
Not reported 
Not reported 
0 
5 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
2 
1 
2.7 (non-dialysis) 
6.0 (dialysis) 
Friedman 
2016 
3717 5 3 11 Not reported Not reported Not reported Not reported 13 Not reported Not reported 
Frommeyer 
2016 
18 1 0 0 0 0 1 0 0 0 0 
Hai 2015 21 0 2 Bleeding in 2 
cases (haematoma 
not specifically 
mentioned) 
4 0 0 0 0 0 0 
Jarman 2013 111 1 11 0 Not reported 2 cases of 
erosion causing 
chronic pain 
2 0 0 1 0.9 
Kobe 2013 69 0 1 1 0 0 0 1 0 1 2.4 
Koman 2016 68 (non-dialysis) 
18 (dialysis) 
0 5 (non-dialysis) 
0 (dialysis) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
0 (non-
dialysis) 
2 (dialysis) 
5 (non-
dialysis) 
2 (dialysis) 
11.1 (non-
dialysis) 
19.8 (dialysis) 
Mithani 2016 71 Not reported 0 1 Not reported 0 Not reported Not reported Not reported 2 5.7 
Smith 2013 73 Not reported 1 Not reported Not reported Not reported 3 Not reported Not reported 3 1.8 
Theuns 2015 55 Not reported 1 Not reported Not reported Not reported 5 Not reported 0 8 2.5 
Torres 2014 73 0 0 2 0 0 0 0 0 Not reported Not reported 
Weinstock 
2016 
16 Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Willner 2015 22 
(submuscular) 
12 
(subcutaneous) 
Not reported 
Not reported 
0 (submuscular) 
1 (subcutaneous 
incision site 
infection) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Rate (%)  0.28 2.66 0.44 0.61 0.75 1.16 0.32 0.35 3.36 2.1 
Figure 1: Flow diagram of study selection 
 
References 
1. Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. Physician procedure 
volume and complications of cardioverter-defibrillator implantation. Circulation 
2012;125:57-64. 
2. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, 
Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in 
implantable cardioverter-defibrillators over a period of 10 years. Circulation 
2007;115:2474-2480. 
3. Gomes S, Cranney G, Bennett M, Giles R. Long-term outcomes following 
transvenous lead extraction. PACE 2016;39:345-351. 
 
4. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, 
Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, 
Spitzer SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder IC, Wilde 
AA, van Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely 
subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363:36-44. 
 
5. Mangels D, Frishman WH. The subcutaneous implantable cardioverter defibrillator. 
Cardiol Rev 2016;24:248-55. 
6. McLeod CJ, Boersma L, Okamura H, Friedman PA. The subcutaneous implantable 
cardioverter defibrillator: state-of-the-art review. Eur Heart J 2015; pii:ehv507. 
7. Lewis GF, Gold MR. Safety and efficacy of the subcutaneous implantable 
defibrillator. J Am Coll Cardiol 2016;67:445-54. 
 
8. Gold MR, Theuns DA, Knight BP, Sturdivant JL, Sanghera R, Ellenbogen KA, Wood 
MA, Burke MC. Head-to-head comparison of arrhythmia discrimination performance 
of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START 
study. J Cardiovasc Electrophysiol 2012;23:359–366. 
9. Olde Nordkamp LR, DabiriAbkenari L, Boersma LV, Maass AH, de Groot JR, van 
Oostrom AJ, Theuns DA, Jordaens LJ, Wilde AA, Knops RE. The entirely 
subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a 
large Dutch cohort. J Am Coll Cardiol 2012;60:1933-9. 
 
10. Aydin A, Hartel F, Schluter M, Butter C, Kobe J, Seifert M, Gosau N, Hoffmann B, 
Hoffmann M, Vettorazzi E, Wike I, Wegscheider K, Reichenspurner H, Eckardt L, 
Steven D, Willems S. Shock efficacy of subcutaneous implantable cardioverter-
defibrillator for prevention of sudden cardiac death. Circ Arrhythm Electrophysiol 
2012;5:913-919. 
 
11. Burke MC, Gold MR, Knight BP, Barr CS, Theuns DA, Boersma LV, Knops RE, 
Weiss R, Leon AR, Herre JM, Husby M, Stein KM, Lambiase PD. Safety and 
efficacy of the totally subcutaneous implantable defibrillator. J Am Coll Cardiol 
2015;65:1605-1615. 
 
12. Eckardt L, Shin DI, Aydin M, Juchem G, Kaab S, Butter C, Kobe J, Willems S, 
Winter J. Initial experience with an entirely subcutaneous implantable cardioverter-
defibrillator. Heart Rhythm 2011;8:S12. 
 
13. El-Chami MF, Levy M, Kelli HM, Casey M, Hoskins MH, Goyal A, Langberg JJ, 
Patel AA, Delurgio D, Lloyd MS, Leon AR, Merchant FM. Outcome of subcutaneous 
implantable cardioverter defibrillator implantation in patients with end-stage renal 
disease on dialysis. J Cardiovasc Electrophysiol 2015;26:900-904.  
 
14. Friedman DJ, Parzynski C, Curtis J, Varosy P, Russo A, Prutkin J, Patton K, Mithani 
A, Al-Khatib S. Early use of the subcutaneous implantable cardioverter defibrillator 
in the United States: a report from the National Cardiovascular Data Registry. J Am 
Coll Cardiol 2016;67:685. 
 
15. Frommeyer G, Dechering DG, Zumhagen S, Loher A, Kobe J, Eckardt L, Reinke F. 
Long-term follow-up subcutaneous ICD systems in patients with hypertrophic 
cardiomyopathy: a single-center experience. Clin Res Cardiol 2016;105:89-93. 
 
16. Hai JJ, Lim ETS, Chan CP, Chan YS, Chan KK, Chong D, Ho KL, Tan BY, Teo WS, 
Ching CK, Tse HF. First clinical experience of the safety and feasibility of total 
subcutaneous implantable defibrillator in an Asian population. Europace 
2015;17:ii63-ii68.  
 
17. Jarman JWE, Todd DM. United Kingdom national experience of entirely 
subcutaneous implantable cardioverter-defibrillator technology: important lessons to 
learn. Europace 2013;15:1158-1165.  
 
18. Kobe J, Reinke F, Meyer C, Shin DI, Martens E, Kaab S, Loher A, Amler S, 
Lichtenberg A, Winter J, Eckardt L. Implantation and follow-up of totally 
subcutaneous versus conventional implantable cardioverter-defibrillators: A 
multicenter case-control study. Heart Rhythm 2013;10:29-36. 
 
19. Koman E, Gupta A, Subzposh F, Saltzman H, Kutalek SP. Outcomes of subcutaneous 
implantable cardioverter-defibrillator implantation in patients on hemodialysis. J 
Interv Card Electrophysiol 2016;45:219-223. 
 
20. Mithani A, Kath H, Eno E, Nathan K, Field J, Hunter K, Ortman M, Andriulli J, 
Russo A. Characteristics and clinical outcomes of patients undergoing subcutaneous 
versus transvenous single chamber ICD placement. J Am Coll Cardiol 2016;67:860.  
 
21. Smith W, Hood M, Riddell F, Crozier I, Melton I, Stiles M. The subcutaneous ICD-
the New Zealand experience. J Interv Card Electrophysiol 2013;36:S113. 
 
22. Theuns DAMJ, Crozier IG, Barr CS, Hood MA, Cappato R, Knops RE, Maass AH, 
Boersma LV, Jordaens L. Longevity of the Subcutaneous Implantable Defibrillator. 
Circ Arrhythm Electrophysiol 2015;8:1159-1163.  
 
23. Torres JL, Kumar S, Kamalov G, Amin A, Hummel J, Daoud E, Augostini R, 
Houmsse M, Kalbfleisch S, Love C, Rhodes T, Tyler J, Weiss R. Subcutaneous 
cardiac defibrillator in patients with congenital heart disease: a single center 
experience. Heart Rhythm 2014;11:S488. 
 
24. Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous implantable 
cardioverter debrillator in patients with hypertrophic cardiomyopathy: an initial 
experience. J Am Heart Assoc 2016;5:pii: e002488. 
 
25. Willner JM, Miller MA, Singh A, Sharma D, Palaniswamy C, Dukipati S, Reddy VY. 
Chronic safety and efficacy of submuscular implantation of a subcutaneous ICD 
system. Heart Rhythm 2015;12:S336. 
 
26. Friedman DJ, Prazynski CS, Varosy PD, Prutkin JM, Patton KK, Mithani A, Russo 
AM, Curtis JP, Al-Khatib SM. Trends and in-hospital outcomes associated with 
adoption of the subcutaneous implantable cardioverter defibrillator in the United 
States. JAMA Cardiol 2016; doi: 10.1001/jamacardio.2016.2782. 
 
27. Van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. 
Implantation-related complications of implantable cardioverter-defibrillators and 
cardiac resynchronization therapy devices: a systematic review of randomized clinical 
trials. J Am Coll Cardiol. 2011;58:995-1000. 
 
28. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, Payne J, 
Strickberger SA, Breiter D, Hahn S. Efficacy and temporal stability of reduced safety 
margins for ventricular defibrillation: primary results from the Low Energy Safety 
Study. Circulation 2002;105:2043-8. 
 
29. Cha YM, Hayes DL, Asirvatham SJ, Powell BD, Cesario DA, Cao M, Gilliam FR 
3rd, Jones PW, Jiang S, Saxon LA. Impact of shock energy and ventricular rhythm on 
the success of the first shock therapy: the ALTITUDE first shock study. Heart 
Rhythm 2013;10:702-8. 
 
30. Kutyifa V, HuthRuwald AC, Aktas MK, Jons C, McNitt S, Polonsky B, Geller L, 
Merkely B, Moss AJ, Zareba W, Bloch Thomsen PE. Clinical impact, safety, and 
efficacy of single- versus dual-coil ICD leads in MADIT-CRT. J Cardiovasc 
Electrophysiol 2013;24:1246-52. 
 
 
31. Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, Dixit S, Verdino 
RJ, Nayak HM, Callans DJ, Patel V, Marchlinski FE. Defibrillation threshold testing: 
is it really necessary at the time of implantable cardioverter-defibrillator insertion? 
Heart Rhythm 2005; 2:456-61. 
 
32. Blatt JA, Poole JE, Johnson GW, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, 
Yee R, Guarnieri T, Talajic M, Wilber DJ, Anderson J, Chung K, Wong WS, Mark 
DB, Lee KL, Bardy GH. No benefit from defibrillation threshold testing in the SCD-
HeFT (Sudden Cardiac Death in Heart Failure Trial).J Am Coll Cardiol. 2008;52:551-
6. 
 
 
 
33. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, 
Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page 
RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs 
AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, 
Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, 
Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline 
Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); 
American Association for Thoracic Surgery; Society of Thoracic 
Surgeons.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac 
Rhythm Abnormalities: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines (Writing Committee to Revise 
the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac 
Pacemakers and Antiarrhythmia Devices): developed in collaboration with the 
American Association for Thoracic Surgery and Society of Thoracic 
Surgeons.  Circulation 2008;117:e350-e408 
 
34. Bernstein NE, Karam ET, Aizer A, Wong BC, Holmes DS, Bernstein SA, Chinitz LA. 
Right-sided implantation and subpectoral position are predisposing factors for fracture 
of a 6.6 French ICD lead. Pacing Clin Electrophysiol 2012;35:659-64. 
 
35. Maisel WH, Hauser RG, Hammill SC, Hauser RG, Ellenbogen KA, Epstein AE, 
Hayes DL, Alpert JS, Berger RD, Curtis AB, Dubin AM, Estes NA 3rd, Gura MT, 
Krahn AD, Lampert R, Lindsay BD, Wilkoff BL. Recommendation from the Heart 
Rhythm Society Task Force on lead performance policies and guidelines: developed 
in collaboration with the American College of Cardiology (ACC) and the American 
Heart Association (AHA). Heart Rhythm 2009;6:869-885. 
 
36. Gold MR, Peters RW, Johnson JW, Shorofsky SR. Complications associated with 
pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and 
submuscular approaches. J Am Coll Cardiol 1996;28:1278-82. 
 
 
37. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, Kutalek SP, 
Sharma A. Dual-chamber pacing or ventricular backup pacing in patients with an 
implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator 
(DAVID) Trial. JAMA 2002;288:3115-23. 
 
38. Scott PA, Whittaker A, Zeb M, Watts E, Yue AM, Roberts PR, Morgan JM. Rates of 
upgrade of ICD recipients to CRT in clinical practice and the potential impact of the 
more liberal use of CRT at initial implant. Pacing Clin Electrophysiol.2012; 35: 73-
80. 
 
39. Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, Gitt A, Limbourg T, 
Linde C, Dickstein K. The European Cardiac Resynchronization Therapy Survey: 
comparison of outcomes between de novo cardiac resynchronization therapy 
implantations and upgrades. Eur J Heart Fail 2011; 13: 974-83. 
 
40. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, Gasparini 
M, Wilde AA, Knops RE, Denjoy I, Toivonen L, Monnig G, Al-Fayyadh M, 
Jordaenes L, Borggrege M, Holmgrens C, Brugada P, De Roy L, Hohnloser SH, 
Brink PA. Who are the long-QT syndrome patients who receive an implantable 
cardioverter-defibrillator and what happens to them?: data from the European Long-
QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. 
Circulation 2010; 122: 1272-82. 
 
41. Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gérard F, Mabo P, Reuter 
S, Lamaison D, Takahashi Y, O'Neill MD, Garrigue S, Pierre B, Jaïs P, Pasquié JL, 
Hocini M, Salvador-Mazenq M, Nogami A, Amiel A, Defaye P, Bordachar P, Boveda 
S, Maury P, Klug D, Babuty D, Haïssaguerre M, Mansourati J, Clémenty J, Le Marec 
H. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada 
syndrome: a multicenter study. Circulation 2006;114:2317-24. 
 
42. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, Dalal D, 
Tedford R, Russell SD, Abrahams T, Tandri H, Judge DP, Calkins H. Incidence and 
predictors of implantable cardioverter-defibrillator therapy in patients with 
arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable 
cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 
2011;58:1485-96. 
 
43. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. 
Device complications and inappropriate implantable cardioverter defibrillator shocks 
in patients with hypertrophic cardiomyopathy. Heart 2009;95:709-14. 
 
44. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, Schuger C, 
Steinberg JS, Higgins SL, Wilber DJ, Klein H, Andrews ML, Hall WJ, Moss AJ. 
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, 
mechanisms, predictors and survival impact. J Am Coll Cardiol 2008;51:1357-65. 
 
45. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, 
Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray 
LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH;. Amiodarone or an implantable 
cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. 
 
46. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-
Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK. 
Strategic programming of detection and therapy parameters in implantable 
cardioverter-defibrillators reduces shocks in primary prevention patients: results from 
the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 
2008; 52: 541-50. 
 
47. Kooiman KM, Knops RE, Olde Nordkamp L, Wilde AA, de Groot JR. Inappropriate 
subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing 
can be prevented: implications for management. Heart Rhythm 2014;11:426-34. 
 
48. Gold MR, Weiss R, Theuns DA, Smith W, Leon A, Knight BP, Carter N, Husby M, 
Burke MC. Use of discrimination algorithm to reduce inappropriate shocks with a 
subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2014;11:1352-8. 
 
49. Olde Nordkamp LR, Warnaars JL, Kooiman KM, de Groot JR, Rosenmoller BR, 
Wilde AA, Knops RE. Which patients are not suitable for a subcutaneous ICD: 
incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc 
Electrophysiol. 2014;25:494-99. 
 
 
 
 
50. Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, Delnoy 
PP, van Dessel PF, Driessen AH, de Groot JR, Herrman JP, Jordaens LJ, Kooiman 
KM, Maass AH, Meine M, Mizusawa Y, Molhoek SG, van Opstal J, Tijssen JG, 
Wilde AA. Rationale and design of the PRAETORIAN trial: a Prospective 
RandomizEd comparison of subcuTaneOus and tRansvenous ImplANtable 
cardioverter-defibrillator therapy. Am Heart J 2012; 163: 753-60. 
Supplementary Table 1: Numbers of device explants 
 
Study ID Total patients Explant for IAS Explant for 
ATP/pacing 
Explant for 
failed DFT 
Explant for 
failed CV 
Explant for 
pocket infection 
Any explant Intervention for 
erosion 
Aydin 2012 40 0 1 1 2 0 4 0 
Burke 2015 882 Not reported 4 Not reported Not reported 14 18 12 events, 11 
patients 
Eckardt 2011 35 Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
El-Chami 2015 52 (non-dialysis) 
27 (dialysis) 
1 (non-dialysis) 
0 (dialysis) 
0 (non-dialysis) 
0 (dialysis) 
0 (non-dialysis) 
0 (dialysis) 
0 (non-dialysis) 
0 (dialysis) 
5 (non-dialysis) 
0 (dialysis) 
6 (non-dialysis) 
0 (dialysis) 
0 (non-dialysis) 
0 (dialysis) 
Friedman 2016 3717 Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Frommeyer 2016 18 1 0 0 0 0 1 0 
Hai 2015 21 0 0 0 0 0 0 0 
Jarman 2013 111 5 0 0 0 4 10 9 
Kobe 2013 69 0 0 0 0 1 3 (2 for 
transplantation) 
0 
Koman 2016 68 (non-dialysis) 
18 (dialysis) 
0 (non-dialysis) 
0 (dialysis) 
Not reported 
Not reported 
0 (non-dialysis) 
0 (dialysis) 
Not reported 
Not reported 
3 extracted for 
infection  
3 (non-dialysis) 
0 (dialysis) 
Not reported 
Not reported 
Mithani 2016 71 Not reported Not reported Not reported Not reported 0 Not reported Not reported 
Smith 2013 73 1 0 0 0 1 6 0 
Theuns 2015 55 0 3 1 0 1 5 0 
Torres 2014 73 0 1 0 0 0 1 0 
Weinstock 2016 16 Not reported Not reported Not reported Not reported Not reported Not reported Not reported 
Willner 2015 22 (submuscular) 
12 (subcutaneous) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Event rate from 
combined studies 
(%) 
 1.28 0.63 0.32 0.37 1.83 3.76 1.47 
 
Supplementary Table 2: Defibrillation testing 
 
Study ID Total patients DFT performed (%) DFT successful on first 
attempt (%) 
DFT successful after reprogramming DFT successful after generator reposition 
Aydin 2012 40 40 (100) 39 (98) 0 0 
Burke 2015 882 Not reported Not reported Not reported Not reported 
Eckardt 2011 35 33 (94) 23 (70) 4 (12) 2 (6) 
El-Chami 2015 52 (non-dialysis) 
27 (dialysis) 
46 (88; non-dialysis) 
20 (74; dialysis) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Friedman 2016 3717 2791 (75) Not reported Not reported Not reported 
Frommeyer 2016 18 17 (94) 15 (88) 2 (12) Not necessary 
Hai 2015 21 20 (95) Not reported Not reported Not reported 
Jarman 2013 111 Not reported Not reported Not reported Not reported 
Kobe 2013 69 67 (97) 58 (87) 6 (9) 2 (3) 
Koman 2016 68 (non-dialysis) 
18 (dialysis) 
60 (88; non-dialysis) 
16 (89; dialysis) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Mithani 2016 71 Not reported Not reported Not reported Not reported 
Smith 2013 73 Not reported Not reported Not reported Not reported 
Theuns 2015 55 Not reported Not reported Not reported Not reported 
Torres 2014 73 72 (99) Not reported Not reported Not reported 
Weinstock 2016 16 15 (94) 15 (100) Not necessary Not necessary 
Willner 2015 22 (submuscular) 
12 (subcutaneous) 
29 in total (85) 29 (100) Not necessary Not necessary 
Event rate from 
combined studies 
(%) 
 77 91   
 
Supplementary Table 3: Inappropriate shocks 
 
Study ID Total patients Patients with IAS Total no. of IAS IAS: TWOS IAS: SVT IAS: noise/myopotentials 
Aydin 2012 40 2 (5) 2 0 2 0 
Burke 2015 882 14 (2) Not reported 8 6 Not reported 
Eckardt 2011 35 Not reported Not reported Not reported Not reported Not reported 
El-Chami 2015 52 (non-dialysis) 
27 (dialysis) 
5 (10; non-dialysis) 
1 (4; dialysis) 
5 (non-dialysis) 
1 (dialysis) 
3 (non-dialysis) 
1 (dialysis) 
1 (non-dialysis) 
0 (dialysis) 
1 (non-dialysis) 
0 (dialysis) 
Friedman 2016 3717 Not reported Not reported Not reported Not reported Not reported 
Frommeyer 2016 18 4 (22) 11 4 0 0 
Hai 2015 21 0 (0) 0 0 0 0 
Jarman 2013 111 17 (15) 51 41/51 4/51 6/51 
Kobe 2013 69 3 (4) 3 3 0 0 
Koman 2016 68 (non-dialysis) 
18 (dialysis) 
5 (8; non-dialysis) 
2 (11; dialysis) 
Not reported 
Not reported 
1 (non-dialysis) 
1 (dialysis) 
2 (non-dialysis) 
1 (dialysis) 
2 (non-dialysis) 
0 (dialysis) 
Mithani 2016 71 1 (1) Not reported Not reported Not reported Not reported 
Smith 2013 73 9 (12) Not reported Not reported Not reported Not reported 
Theuns 2015 55 Not reported Not reported Not reported Not reported Not reported 
Torres 2014 73 2 (3) Not reported 2 Not reported Not reported 
Weinstock 2016 16 1 (6) 1 0 0 0 
Willner 2015 22 (submuscular) 
12 (subcutaneous) 
1 (5; submuscular) 
1 (8; subcutaneous) 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Event rate from 
combined studies 
(%) 
 4.3     
 
 
